The markets traded lower during the midday with the Dow losing 60 points to 16,373 as Asian markets dropped. Nasdaq fell 15 points to 4,806.
On the upside
A Food and Drug Administration advisory committee unanimously recommended approval of Collegium Pharmaceutical’s (Nasdaq: COLL) abuse-deterrent pain treatment Xtampza.
Trevena (Nasdaq: TRVN) will raise funds through the issuance and sale of 6.5 million common shares.
Chesapeake Energy (NYSE: CHK) chief executive Doug Lawler assured investors that the company will maximize liquidity and cash generation.
On the downside
SunEdison (NYSE: SUNE) partnered with SOLON to provide Pima County, Arizona, with 5 megawatts of solar power but the stock price fell.
Retreating copper prices weighed down shares of Freeport-McMoRan (NYSE: FCX).
Northland Capital slashed its price target on Marvell Technology (Nasdaq: MRVL) from $15 to $9.
In the broad market, declining issues outpaced advancers by a margin of nearly 2 to 1 on the NYSE and by nearly 5 to 3 on Nasdaq. The broader S&P 500 lost 6 points to 1,954. Bitcoin rose $2 to $230.